Introduction {#sec1}
============

Dementia is a severe neurodegenerative disorder, affecting 1.5% of the population at the age of 65, and \>20% at the age of 85 ([@ref102]). The morbidity and mortality of dementia are high. For elderly people aged between 65 and 85 years, the prevalence rate of dementia doubles every 5 years ([@ref35]). About 24.3 million people worldwide were diagnosed with dementia in 2005 ([@ref32]). In 2010, 35 million people had dementia worldwide ([@ref11]). The population of people with dementia is estimated to be 65 million by 2030 and 113 million by 2050 ([@ref11]). The prevalence rate has been rising fast in the rapid-aging society ([@ref98]).

The etiology of dementia remains unclear. Its increasing prevalence rate contributes to both a health and social problem, resulting in heavy caregiver burdens and economic impacts to the societies ([@ref1]). Age and female gender are two major risk factors for Alzheimer's disease (AD), which is the main cause of dementia; two-thirds of elderly people with AD are women. Even regarding the difference in longevity, studies suggest that women are still at a higher risk ([@ref98]). Precision medicine approaches have advanced our understanding of the development and treatment of AD dementia. However, gender has not yet been adequately addressed by many of these approaches. More attention to gender differences will improve outcomes for people with dementia ([@ref90]). Previous research on NMDAR function has focused on cognition, particularly learning and memory. The current article focuses on mood or other psychological symptoms rather than memory.

Behavioral and Psychological Symptoms of Dementia is Common and Detrimental in Demented Patients {#sec2}
================================================================================================

One of the most troublesome domains of treating dementia is the behavioral and psychological symptoms of dementia (BPSD). The term "BPSD" was first described in late 1980s, and was then defined as "a term used to describe a heterogeneous range of psychological reactions, psychiatric symptoms, and behaviors occurring in people with dementia of any etiology" in the 1996 International Psychogeriatric Association (IPA) consensus conference ([@ref33]). BPSD can be classified into four domains: (1) disorders of thought content, including delusions, suspiciousness, etc. ([@ref12]); (2) disorders of perception, including misidentification syndromes, hallucinations, etc. ([@ref13]); (3) disorders of mood, including elevated mood, anxiety, depression, etc. ([@ref14]); and (4) disorders of behavior, including agitation, aggression, wandering, binge-eating, hyperorality, sexual disinhibition, urinary incontinence, etc. ([@ref15]).

BPSD is common among patients with dementia. Sixty-four percent of dementia patients revealed BPSD at initial evaluation ([@ref27]) and 90% of them had BPSD over the whole dementia course ([@ref115]). In Taiwan, the prevalence rate of all types of BPSD in patients with AD is around 20--60%, varying with different symptoms ([@ref36]). About 30--60% patients with AD have delusion, 21--26% hallucination, 35--76% anxiety, 22--50% depression, and 26--61% sleep abnormalities ([@ref36]).

The manifestations of BPSD vary with different types and stages of dementia. Mood symptoms are usually more common while psychotic symptoms are less common in vascular dementia (VaD) ([@ref91]). In Eastern Asia, patients with AD had a high incidence of anxiety/phobia (61.2%) and people with VaD had more paranoid and delusional ideation (71.9%) and affective disturbance (46.9%) ([@ref21]). Depression is more commonly observed in early stages of dementia while psychosis occurs more often in later stages ([@ref95]; [@ref103]). Furthermore, the severity of BPSD is often associated with the stage of dementia ([@ref121]). It is believed that BPSD without adequate treatment leads to poorer prognosis of dementia ([@ref9]; [@ref108]; [@ref10]; [@ref57]).

No Current Medication is Approved by Food and Drug Administration for Treating Behavioral and Psychological Symptoms of Dementia {#sec3}
================================================================================================================================

Despite the high prevalence rate of BPSD and its hazards in patients with dementia, there has not yet been medication that is effective and approved for the treatment of BPSD by the Food and Drug Administration (FDA) ([@ref110]). The efficacy of antipsychotics for the treatment of BPSD is scanty ([@ref105]). In addition, there is safety concern for antipsychotics use in BPSD ([@ref73]; [@ref104]). Furthermore, atypical antipsychotics may worsen the cognitive decline in patients with AD ([@ref133]), implying that antipsychotics may not be the best remedy for BPSD.

The efficacy of acetylcholinesterase inhibitors (AChEIs), which are the current main medication for AD, for treating BPSD is controversial ([@ref57]).

N-Methyl-D-Aspartate Receptor and the Pathogenesis of Dementia and Behavioral and Psychological Symptoms of Dementia {#sec4}
====================================================================================================================

N-methyl-D-aspartate receptors (NMDARs) exert multiple activities including two opposite ones: neurotoxicity and neurotrophic effects. Both NMDAR hypofunction and excitotoxicity are implicated in neurodegeneration. NMDAR activation is critical for synaptic plasticity, learning, and memory ([@ref118]; [@ref141]; [@ref89]; [@ref39]). Attenuation of NMDAR neurotransmission can result in loss of neuronal plasticity and cognitive deficits ([@ref23]; [@ref53]). Moreover, hypo-NMDAR function induced by NMDAR antagonists is neurotoxic, accounting for deterioration and brain atrophy ([@ref92]).

NMDAR plays a vital role in the pathogenesis of AD. Compared with healthy controls, individuals with AD have fewer NMDARs in the frontal cortex and hippocampus ([@ref99]), lower CSF concentrations of excitatory amino acids ([@ref84]), lower serum levels of D-serine ([@ref52]), and reduced D-aspartate uptake ([@ref81]). In a mouse model of AD, expression of surface NMDARs decreases in neurons ([@ref112]). Amyloid-β peptide (Aβ), which is the pathological hallmark for AD, can impair NMDAR signal transduction and synaptic function ([@ref109]; [@ref139]; [@ref22]). Apolipoprotein E4, an amyloid binding protein isoform related to the AD risk, also decreases NMDAR functions in patients with AD ([@ref20]). Loss of presenilins reduces NMDAR-mediated responses and synaptic levels of NMDAR subunits, thereby affecting both short- and long-term plasticity in AD pathogenesis ([@ref97]).

N-Methyl-D-Aspartate Receptor Inhibiting Agents {#sec5}
===============================================

Memantine, an NMDAR partial antagonist and a drug for treating moderate-to-severe AD, had conflicting data in the treatment of neuropsychiatric symptoms in dementia from randomized controlled trials ([@ref101]; [@ref120]; [@ref110]). In subsequent individual studies and pooled analyses ([@ref41], [@ref40]; [@ref136]), memantine had some benefits in the treatment of irritability/liability, agitation/aggression, and psychosis in patients with AD, but stronger evidence from randomized controlled trials for BPSD is still lacking ([@ref2]). Lately, memantine's effect for BPSD has been found to be boosted by combination of citalopram, an antidepressant ([@ref142]). Of note, an initial reason for the use of memantine to treat AD is the hypothesis that activity of the NMDAR could be a mechanism for cell death ([@ref34]). Thus, a potential fear is that enhancing NMDAR function would adversely affect the trajectory of dementia. This may be true for a subclass of dementia. On the other hand, another hypothesis ([@ref34]) also indicates that NMDAR hypofunction is more detrimental to the progression of AD and that the use of memantine as a treatment may be more detrimental, producing cognitive impairments.

Inhibition of NMDAR function by NMDAR antagonists, such as ketamine or phencyclidine, produces psychotic/behavioral symptoms or relevant physiological reactions ([@ref94]; [@ref17]; [@ref77]). However, the NMDAR antagonist ketamine has been shown to exhibit antidepressant effects ([@ref29]). Since depression is one of the BPSD symptoms, whether ketamine and its derivatives, as rapid-acting antidepressants, are beneficial for BPSD treatment deserves further studies ([@ref113]).

NMDAR dysfunction is also involved in ischemic stroke and vascular dementia. Although some studies revealed serum glutamate elevation in acute phase of ischemia stroke ([@ref47]; [@ref83]), this increment of glutamate was only found 10--30 min after ischemic injury ([@ref5]). Similarly, NMDAR hyperfunction occurs very briefly after brain injury; soon after the acute glutamate elevation, profound NMDAR hypofunction ensues and lasts for \>7 days ([@ref7]). In fact, trials using NMDAR antagonists in the treatment of stroke have failed ([@ref60]).

N-Methyl-D-Aspartate Receptor Enhancing Agents {#sec6}
==============================================

Enhancing NMDA neurotransmission can improve memory and behavior symptoms of both dementia and schizophrenia ([@ref44]; [@ref70]). Clinical characteristics of BPSD, such as hallucinations, delusions, disorganized speech, and disturbing behavior, resemble positive symptoms of schizophrenia. Social withdrawal, apathy, alogia, and avolition, which resemble negative symptoms in schizophrenia, and behavior, sleep, or affective problems, are also frequently seen in patients with schizophrenia.

Augmentation through the NMDA-glycine site, a co-agonist site, is preferred to avoid the excitotoxicity ([@ref26]; [@ref24]; [@ref48]; [@ref140]; [@ref56]). Clinically, D-cycloserine, a partial agonist of the NMDA-glycine site, can improve cognitive functions of demented patients ([@ref106]; [@ref124]). There are also several studies that suggest no benefit of D-cycloserine in AD patients ([@ref100]; [@ref30]; [@ref123]). Several possible reasons may explain the discrepancies; the lack of effect may be due to the dose or symptoms examined. Alternatively, the effects of D-cycloserine may depend on the stage of dementia. Since D-cycloserine appears to have benefits in improving cognition ([@ref62]; [@ref93]; [@ref65],[@ref66]; [@ref31]), it may have differential effects on mood and learning depending on the stage of dementia.

Since D-serine is more potent than D-cycloserine and glycine as the glycine co-agonist site of the NMDAR ([@ref54]; [@ref77]), one method to enhance NMDAR function is to inhibit activity of D-amino acid oxidase (DAAO), which is responsible for degrading D-serine and D-alanine ([@ref37]; [@ref131]). One of the candidates of DAAO inhibitors is benzoic acid and its salt, sodium benzoate. They can inhibit DAAO activity and thereby raise synaptic concentrations of D-serine both *in vitro* and in animal studies ([@ref130]).

Several clinical trials have shown the potential of NMDAR-enhancing agents \[for example, sarcosine (a glycine transporter I inhibitor) and sodium benzoate\] in alleviating psychotic symptoms of schizophrenia ([@ref68], [@ref69], [@ref72], [@ref71], [@ref70]; [@ref78]), in treating major depressive disorder ([@ref58]), in decreasing oppositional defiant disorder symptoms of attention deficit hyperactivity disorder ([@ref129]), and in reducing neuropsychiatric symptoms of Parkinson's disease with dementia ([@ref125]).

In a 6-week, randomized, double-blind, placebo-controlled trial in patients with schizophrenia (\<65 year old), sodium benzoate (1 g/day) adjunctive therapy was significantly better than placebo in reducing positive and negative symptoms and in improving Global Assessment of Functioning, and revealed favorable safety ([@ref70]). The effect size of sodium benzoate treatment for Positive and Negative Syndrome Rating Scale (PANSS) total score from baseline to endpoint was 1.26, much higher than effect size (0.51) of sarcosine adjuvant therapy for the PANSS total score in chronic schizophrenia patients ([@ref126]). It is noteworthy that sodium benzoate treatment was significantly better than placebo in improving cognitive functions, such as processing speed and visual memory ([@ref70]). In another clinical trial on mild cognitive impairment or mild AD, a total of 60 patients were randomized into sodium benzoate or placebo group. The patients also tolerated sodium benzoate 250--1,500 mg/day well without evident side effects. Interestingly, the patients taking sodium benzoate improved more in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and other cognitive assessments than placebo ([@ref76]).

Of note, a single nucleotide polymorphism (rs2153674) in the G72 (D-amino acid oxidase activator, DAOA, responsible for metabolism of D-serine) gene is associated with the occurrence of psychotic symptoms in patients with AD ([@ref28]). In addition, affinity of the glycine recognition sites of NMDARs was related with the anxiety tone, one domain of BPSD, in patients with AD ([@ref127]). Therefore, it is possible that NMDAR-enhancing agents, which have been demonstrated to be effective in treating schizophrenia, depression, and other psychiatric symptoms, could also be used in the treatment of BPSD.

Moreover, stimulation of NMDARs 24 and 48 h after brain injury could attenuate neurological deficits and improve cognitive performance, implying that NMDAR function is crucial for neural repair in subacute or chronic stroke ([@ref7]). The aforementioned studies suggest the potential use of DAAO inhibitors for the treatment of BPSD.

Gender Difference in N-Methyl-D-Aspartate Receptor Function {#sec7}
===========================================================

Age and female gender are two major risk factors for AD; two-thirds of elderly people with AD are women. Even regarding the difference in longevity, studies suggest that women are still at a higher risk ([@ref98]). However, gender has not yet been adequately addressed by many of these approaches. More attention to gender differences will improve outcomes for demented people ([@ref90]).

A previous study showed that female rats were much more susceptible to NMDAR modulation than males ([@ref55]). Another study found that the average density of NMDAR currents was 2.8-fold larger in dorsal root ganglia of female rats than that of male rats, and that addition of 17-ß-estradiol (E2) increased NMDAR currents by 55% in female neurons, but only 19% in male, indicating sex differences in the activity and estrogen modulation of NMDAR ([@ref87]). Further, estrogen also plays a role in NMDAR function during aging ([@ref132]; [@ref3]). E2 treatment can enhance the long-term potentiation (LTP) magnitude at CA3-CA1 synapses, NMDAR/AMPAR ratio, GluN2B-mediated NMDAR current, hippocampal CA1 dendritic spine density, and novel object recognition (NOR), a task that requires hippocampal NMDARs, in female rats during a critical period between 9 and 15 months, but not at 19 months post-ovariectomy (OVX) ([@ref111]; [@ref132]).

Sex hormones were found to modulate hippocampal NMDAR expression in mice ([@ref85]), and interact with circulating antioxidants in human blood ([@ref4]). Noteworthily, benzoic acid ester of estrone, a precursor of estradiol, has prolonged duration of action ([@ref67]), suggesting that benzoate may interact with female sex hormone ([@ref74]).

Whether benzoate can improve cognitive function and the behavioral symptoms in patients with BPSD in a gender-specific manner deserves investigation. Further study is needed to verify the possible mediating roles of sex hormones in benzoate effect for dementia and its associated BPSD.

Hunting for Peripheral Biological Markers of Dementia {#sec8}
=====================================================

At present, the diagnosis of dementia mainly relies on clinical manifestation. There was no satisfactory laboratory test from the peripheral approach for the diagnosis of dementia. There have been lots of postmortem brain studies in fields of AD and related neurodegenerative disorders ([@ref19]; [@ref116]). It was highly concerning that RNA expressions might be affected by many factors (e.g., coma. hypoxia) under postmortem condition ([@ref122]). A peripheral measurable marker is needed, to enable a simple, more rapid, and more accurate diagnosis and monitoring ([@ref61]; [@ref79]).

It is proposed that white blood cells and lymphocytes may serve as neural probes since there are similarities of signal transduction and receptor expression between peripheral blood cells and neurons/glia ([@ref42]). A blood-derived sample will be a more feasible alternative to brain tissue biopsy if the gene expressions are synchronized in both ([@ref128]). For example, Hye et al. reported that glycogen synthase kinase-3 was increased in both AD and mild cognitive impairment patients ([@ref59]). However, some molecules would be not suitable for serving as biomarkers, due to the large overlap between patient and control groups.

Potential Peripheral Predictors for Treatment Response of N-Methyl-D-Aspartate Receptor Enhancers {#sec9}
=================================================================================================

Precision medicine approaches have advanced our understanding of the development and treatment of dementia. Many genes which lie in different pathways were found to be associated with susceptibility of dementia and/or psychosis. Genes on the pathways, which are associated with the metabolism of D-amino acids, glycine and glutamate, may be able to regulate the NMDAR function.

D-Amino Acids Metabolism {#sec10}
------------------------

D-amino acid oxidase activator (DAOA, or named G72) protein regulates DAAO activity ([@ref43]), enhances metabolism of D-serine and D-alanine, and can attenuate NMDAR neurotransmission. D-serine is generated from L-serine by serine racemase (SRR) ([@ref138]) and degraded by DAAO ([@ref88]). Over the past few years, more than 30 studies have demonstrated the association of DAAO and G72 with schizophrenia ([@ref8]). Diminished D-serine along with elevation in L-serine also suggests the dysfunction of SRR activity ([@ref51]). DAAO is implicated in oxidative stress ([@ref114]; [@ref82]). Studies indicated that the DAAO level in peripheral blood increased with the severity of cognitive deficits in the elderly ([@ref80]) and decreased after 6-week treatment of sodium benzoate (a DAAO inhibitor) in patients with schizophrenia ([@ref75]). It is hypothesized that G72, DAAO, and SRR, which regulate the metabolism of the main co-agonist of the NMDAR, D-serine, are associated with dementia and its BPSD.

Glycine Metabolism {#sec11}
------------------

Glycine, a co-agonist of the NMDAR, is abundant throughout the brain and serves as a major inhibitory neurotransmitter in the hindbrain. Serine hydroxymethyltransferase (SHMT) is the enzyme which cleaves serine into glycine ([@ref25]). The activity of SHMT was significantly lower in psychotic individuals than in nonpsychotic ones ([@ref134]). Phosphoserine aminotransferase (PSAT) enzyme accounts for the serine biosynthesis ([@ref96]). Patients with PSAT deficiency manifest a broad spectrum of neuropsychiatric symptoms clinically ([@ref50]). Glycine C-acetyltransferase, also known as GCAT, acts in concert with L-threonine 3-dehydrogenase (TDH) in the degradation of threonine to form glycine ([@ref86]). Aminomethyltransferase (AMT) is an enzyme that catabolizes the creation of methylenetetrahydrofolate. It is part of the glycine decarboxylase complex.

Glutamate Metabolism {#sec12}
--------------------

Glutamate is the most abundant amino acid neurotransmitter in the mammalian brain. Glutamatergic neurotransmission has drawn attention for its role in the pathophysiology of many mental illnesses ([@ref77]). The extracellular concentration of glutamate is regulated by the action of transporter proteins, which include glial high-affinity glutamate transporter, member 3 (SLC1A3) ([@ref63]) and neutral amino acid transporter (ASCT1) ([@ref135]). Glutamate receptor, metabotropic 3 (GRM3) ([@ref18]) and glutamate receptor, ionotropic, kainate 1 (GluR5) ([@ref137]) are among the genes related to the glutamatergic neurotransmission systems. Glutamate decarboxylase 1 (GAD1), encoding the 67-kDa isoform of glutamate decarboxylase, is the key enzyme for GABA biosynthesis and is expressed at altered levels in postmortem brain of subjects diagnosed with schizophrenia and related psychotic disorders ([@ref117]).

Increased oxidative stress also contributes to aging processes and neurodegenerative diseases ([@ref38]; [@ref107]; [@ref16]), while free radicals damage cells and tissues ([@ref49]). Antioxidants may help to prevent and reverse cognitive deficits induced by free radicals ([@ref45]; [@ref6]; [@ref119]). Studies indicate a link among age-related NMDAR dysfunction, oxidative stress, and senescence and related cognitive decline ([@ref46]; [@ref64]).

Summary {#sec13}
=======

BPSD appears the hardest-to-treat domain of dementia. Non-pharmacological approaches are the mainstream treatment; however, psychotropics are still needed for a substantial portion of patients. While second-generation antipsychotics have been widely used for the treatment for BPSD, their adverse effects generally offset the benefits. To date, no pharmacological approach has been approved for the treatment of BPSD.

Lately, NMDAR activating strategies, such as DAAO inhibition, have been demonstrated to benefit early-phase dementia as well as psychotic disorders such as schizophrenia. Whether such a novel medical route can also improve BPSD (or a fraction of it, with the aid of molecular precision medicine) deserves studies.

Since BPSD is difficult to treat, it is important to identify subpopulations that tend to respond to certain treatments. Recent studies suggest that the NMDAR expression may be different between female and male species. Genes involved in the pathways associated with the regulation of NMDAR might be altered in BPSD, and have potential to be developed as biomarkers for detecting dementia and predicting the treatment response.

In summary, the review addressed the NMDAR-related modulation and precision medicine in BPSD. Future studies examining the NMDAR modulators with the aid of potential biomarkers to tailor the treatment for individualized patients with BPSD will advance the treatment of BPSD.
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